

Title (en)

TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF

Title (de)

GEZIELTE ARZNEIMITTELRETTUNG MIT NEUARTIGEN ZUSAMMENSETZUNGEN, KOMBINATIONEN UND VERFAHREN DAFÜR

Title (fr)

TARGETED DRUG RESCUE AVEC DE NOUVELLES COMPOSITIONS, ASSOCIATIONS ET PROCÉDÉS CORRESPONDANTS

Publication

EP 3618819 A4 20210120 (EN)

Application

EP 18794381 A 20180503

Priority

- US 201762501696 P 20170504
- US 2017048748 W 20170825
- TW 106129169 A 20170828
- US 201862634162 P 20180222
- US 201862635554 P 20180227
- US 201862636099 P 20180227
- US 201862636171 P 20180228
- US 2018030978 W 20180503

Abstract (en)

[origin: WO2018204713A1] Compounds of Formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of Formula I, or enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof, wherein the compound is double and/or triple agent or ligand for CYP2D6, 5-HT2A, and/or 5HT2C receptors, and/or acetylcholinesterase are provided.

IPC 8 full level

A61K 31/138 (2006.01); **A61K 9/20** (2006.01); **A61K 31/13** (2006.01); **A61K 31/195** (2006.01); **A61K 31/225** (2006.01); **A61K 31/439** (2006.01); **A61K 31/485** (2006.01); **A61K 45/06** (2006.01); **A61K 47/36** (2006.01); **A61K 47/60** (2017.01); **A61P 9/00** (2006.01); **A61P 25/00** (2006.01)

CPC (source: EP IL KR RU)

A61K 31/13 (2013.01 - EP IL KR); **A61K 31/135** (2013.01 - KR RU); **A61K 31/138** (2013.01 - KR RU); **A61K 31/195** (2013.01 - EP KR); **A61K 31/215** (2013.01 - KR RU); **A61K 31/225** (2013.01 - EP IL KR); **A61K 31/439** (2013.01 - EP IL KR); **A61K 31/485** (2013.01 - EP IL KR RU); **A61K 45/06** (2013.01 - EP KR); **A61P 25/00** (2018.01 - EP IL KR RU); **A61K 2300/00** (2013.01 - IL KR)

C-Set (source: EP)

1. **A61K 31/439 + A61K 2300/00**
2. **A61K 31/225 + A61K 2300/00**
3. **A61K 31/485 + A61K 2300/00**
4. **A61K 31/13 + A61K 2300/00**
5. **A61K 31/195 + A61K 2300/00**
6. **A61K 31/138 + A61K 2300/00**
7. **A61K 31/135 + A61K 2300/00**

Citation (search report)

- [Y] WO 2014011590 A2 20140116 - JAVITT DANIEL C [US]
- [Y] WO 2004006930 A1 20040122 - AVANIR PHARMACEUTICALS [US], et al
- [XY] SOO KYUNG BAE ET AL: "Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. Volume 10, 1 September 2016 (2016-09-01), pages 2959 - 2972, XP055674632, DOI: 10.2147/DDDT.S109141
- [XY] MEIJUAN XU ET AL: "Effect of sarpogrelate hydrochloride on cytochrome P450 2D1/2 in rats", vol. 30, no. 12, 1 January 2014 (2014-01-01), pages 1739 - 1742, XP009519281, ISSN: 1001-1978, Retrieved from the Internet <URL:http://wprim.whocc.org.cn/admin/article/articleDetail?WPRIMID=458713&articleId=458713> DOI: 10.3969/J.ISSN.1001-1978.2014.12.024
- [XY] DOO-YEOUN CHO ET AL: "Selective Inhibition of Cytochrome P450 2D6 by Sarpogrelate and Its Active Metabolite, M-1, in Human Liver Microsomes", DRUG METABOLISM AND DISPOSITION, vol. 42, no. 1, 28 October 2013 (2013-10-28), US, pages 33 - 39, XP055674658, ISSN: 0090-9556, DOI: 10.1124/dmd.113.054296
- See also references of WO 2018204713A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2018204713 A1 20181108; AU 2018261654 A1 20191114; AU 2021215274 A1 20210902; AU 2021215274 B2 20221103; BR 112019022902 A2 20200519; CA 3062452 A1 20181108; CA 3062452 C 20231024; CA 3138116 A1 20181108; CN 110831584 A 20200221; CN 110831584 B 20230310; EP 3618819 A1 20200311; EP 3618819 A4 20210120; IL 270326 A 20180503; IL 270326 B 20221001; IL 270326 B2 20230201; JP 2020518617 A 20200625; JP 2023143940 A 20231006; JP 7514078 B2 20240710; KR 102444803 B1 20220919; KR 20200062078 A 20200603; KR 20210130827 A 20211101; MA 49464 A 20200429; RU 2019137004 A 20210604; RU 2019137004 A3 20210604; RU 2760558 C2 20211129; RU 2760558 C9 20220222; TW 201842902 A 20181216; TW I787260 B 20221221; ZA 201908006 B 20210428

DOCDB simple family (application)

US 2018030978 W 20180503; AU 2018261654 A 20180503; AU 2021215274 A 20210813; BR 112019022902 A 20180503; CA 3062452 A 20180503; CA 3138116 A 20180503; CN 201880037396 A 20180503; EP 18794381 A 20180503; IL 27032619 A 20191031; JP 2019560216 A 20180503; JP 2023119151 A 20230721; KR 20197035796 A 20180503; KR 20217033764 A 20180503; MA 49464 A 20180503; RU 2019137004 A 20180503; TW 107115320 A 20180504; ZA 201908006 A 20191202